Andersen-Tawil syndrome secondary prevention

Jump to navigation Jump to search

Andersen-Tawil syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Andersen-Tawil syndrome from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome secondary prevention

CDC on Andersen-Tawil syndrome secondary prevention

Andersen-Tawil syndrome secondary prevention in the news

Blogs on Andersen-Tawil syndrome secondary prevention

Directions to Hospitals Treating Andersen-Tawil syndrome

Risk calculators and risk factors for Andersen-Tawil syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]; Raviteja Guddeti, M.B.B.S. [3]

Secondary Prevention

Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following:

  • Lifestyle and dietary modifications to avoid known triggers
  • Use of carbonic anhydrase inhibitors (acetazolamide 250-500 mg/1-2x/day or dichlorphenamide 50-100 mg/1-2x/day)
  • Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (>4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias.
  • An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope
  • Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function.

Drugs to Avoid

  • Affected individuals should avoid medications known to prolong QT intervals.
  • Salbutamol inhalers, which may be used in the treatment of primary hyperkalemic periodic paralysis, should be avoided because of the potential for exacerbation of cardiac arrhythmias.
  • Thiazide and other potassium-wasting diuretics may provoke drug-induced hypokalemia and could aggravate the QT interval.

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of Andersen-Tawil syndrome (ATS) include avoidance of some antiarrhythmic drugs and anesthetic precautions.

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of Andersen-Tawil syndrome (ATS) include:

  • Antiarrhythmic drugs: Antiarrhythmic drugs should be used with extra caution as the drugs may deteriorate the neuromuscular symptoms. Which include
    • Lidocaine
    • Mexiletine
    • Propafenone
    • Quinidine
  • Anesthetic care: Care should be taken to avoid malignant hyperthermia when giving anesthesia to the patients of Andersen-Tawil syndrome (ATS).

References


Template:WikiDoc Sources CME Category::Cardiology